Mooncakes Under The Sun: Can China's ‘Name And Shame’ Rule Create Level Playing Field?
China's proposal to register all medical sales reps could lead to the eventual elimination of kickbacks to physicians. Experts say it's the first step towards creating a level compliance playground for multinational and domestic drug makers.
You may also be interested in...
Shanghai is significantly tightening its grip on pharma commercial activities with two new rules in August. One restricts medical sales reps from visiting physicians outside a pre-set time and location, and another requires drug makers to register their sales reps with the local FDA.
Tough new rules from China’s State Council have put the country’s one million medical reps into limbo as their employers scrabble to get to grips with broad curbs on sales activities.
Prices of direct acting hepatitis C drugs are down by 85% in China, with cancer and antidiabetes therapy costs cut by 65% and drug makers are rushing to celebrate. Scrip delves into the considerations behind the low prices and whether industry's excitement is a bit premature.